Tempest Therapeutics IncNASDAQ:TPST
- LAST PRICE1.8500
- TODAY'S CHANGE (%)-0.2000 (-9.7561%)
- Bid / Lots1.7300/ 10
- Ask / Lots1.9900/ 1
- Open / Previous Close2.0300 / 2.0500
- Day Range
- 52 Week Range
- Volume142,808
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TPST |
|---|---|---|
| 09:34 ET | 100 | 2.03 |
| 09:39 ET | 600 | 2.01 |
| 09:41 ET | 100 | 2.04 |
| 09:43 ET | 3284 | 1.9899 |
| 09:50 ET | 1574 | 1.98 |
| 09:54 ET | 2100 | 1.94 |
| 10:10 ET | 475 | 1.9599 |
| 10:19 ET | 944 | 1.9203 |
| 10:39 ET | 3920 | 1.9201 |
| 10:42 ET | 400 | 1.93 |
| 10:44 ET | 6120 | 1.92 |
| 10:46 ET | 3431 | 1.92 |
| 11:00 ET | 100 | 1.8856 |
| 11:08 ET | 5100 | 1.89 |
| 11:13 ET | 500 | 1.88 |
| 11:15 ET | 100 | 1.88 |
| 11:18 ET | 1809 | 1.8899 |
| 11:22 ET | 7300 | 1.89 |
| 11:24 ET | 100 | 1.89 |
| 11:26 ET | 400 | 1.89 |
| 11:31 ET | 100 | 1.906 |
| 11:33 ET | 1500 | 1.89 |
| 11:36 ET | 1000 | 1.89 |
| 11:38 ET | 200 | 1.89 |
| 11:40 ET | 200 | 1.89 |
| 12:03 ET | 895 | 1.87 |
| 12:12 ET | 2550 | 1.9 |
| 12:25 ET | 200 | 1.88 |
| 12:27 ET | 750 | 1.8887 |
| 12:36 ET | 200 | 1.8711 |
| 12:43 ET | 881 | 1.87 |
| 12:48 ET | 785 | 1.86 |
| 12:50 ET | 100 | 1.8645 |
| 12:52 ET | 5700 | 1.85 |
| 12:56 ET | 1300 | 1.835 |
| 12:59 ET | 600 | 1.85 |
| 01:03 ET | 1200 | 1.85 |
| 01:06 ET | 100 | 1.85 |
| 01:08 ET | 400 | 1.85 |
| 01:14 ET | 100 | 1.848 |
| 01:15 ET | 3300 | 1.83 |
| 01:26 ET | 6504 | 1.835 |
| 01:32 ET | 1000 | 1.822 |
| 01:35 ET | 300 | 1.83 |
| 01:37 ET | 300 | 1.81 |
| 01:48 ET | 300 | 1.81 |
| 01:50 ET | 2297 | 1.8 |
| 01:51 ET | 100 | 1.7744 |
| 01:53 ET | 100 | 1.79 |
| 01:57 ET | 100 | 1.79 |
| 02:00 ET | 300 | 1.78 |
| 02:04 ET | 740 | 1.7799 |
| 02:06 ET | 2060 | 1.78 |
| 02:08 ET | 2232 | 1.7999 |
| 02:11 ET | 1800 | 1.78 |
| 02:13 ET | 800 | 1.7601 |
| 02:15 ET | 100 | 1.76 |
| 02:18 ET | 100 | 1.7601 |
| 02:20 ET | 3000 | 1.7601 |
| 02:22 ET | 4300 | 1.76 |
| 02:24 ET | 609 | 1.76 |
| 02:27 ET | 1000 | 1.7899 |
| 02:36 ET | 500 | 1.79 |
| 02:38 ET | 1500 | 1.8 |
| 02:40 ET | 2600 | 1.78 |
| 02:44 ET | 400 | 1.8 |
| 02:45 ET | 1500 | 1.78 |
| 02:47 ET | 400 | 1.8 |
| 02:51 ET | 600 | 1.8 |
| 02:58 ET | 300 | 1.8 |
| 03:00 ET | 300 | 1.8 |
| 03:02 ET | 200 | 1.8 |
| 03:03 ET | 300 | 1.8 |
| 03:07 ET | 720 | 1.8 |
| 03:09 ET | 1500 | 1.82 |
| 03:12 ET | 100 | 1.81 |
| 03:14 ET | 200 | 1.82 |
| 03:16 ET | 400 | 1.82 |
| 03:18 ET | 200 | 1.82 |
| 03:20 ET | 2289 | 1.81 |
| 03:25 ET | 600 | 1.82 |
| 03:27 ET | 3098 | 1.81 |
| 03:34 ET | 600 | 1.82 |
| 03:36 ET | 400 | 1.82 |
| 03:38 ET | 900 | 1.82 |
| 03:39 ET | 500 | 1.82 |
| 03:45 ET | 3600 | 1.791 |
| 03:48 ET | 610 | 1.791 |
| 03:50 ET | 300 | 1.8 |
| 03:52 ET | 900 | 1.84 |
| 03:54 ET | 1500 | 1.84 |
| 03:56 ET | 1882 | 1.8101 |
| 03:57 ET | 2800 | 1.85 |
| 03:59 ET | 4792 | 1.85 |
May 25, 2023
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers, from 5:00PM ET on Thursday May 25, 2023 by GlobeNewswire
5:00PM ET on Thursday May 25, 2023 by GlobeNewswire
May 19, 2023
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday May 19, 2023 by GlobeNewswire
4:05PM ET on Friday May 19, 2023 by GlobeNewswire
May 10, 2023
BRIEF-Tempest Reports First Quarter 2023 Financial Results And Provides Business Update, from 5:53PM ET on Wednesday May 10, 2023 by Thomson Reuters
5:53PM ET on Wednesday May 10, 2023 by Thomson ReutersTempest Reports First Quarter 2023 Financial Results and Provides Business Update, from 4:16PM ET on Wednesday May 10, 2023 by GlobeNewswire
4:16PM ET on Wednesday May 10, 2023 by GlobeNewswire
Apr 28, 2023
Top Midday Gainers, from 1:51PM ET on Friday Apr 28, 2023 by MT Newswires
1:51PM ET on Friday Apr 28, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tempest Therapeutics Inc | 21.4M | -0.7x | --- |
Forte Biosciences Inc | 21.5M | -1.1x | --- |
PaxMedica Inc | 21.1M | -0.9x | --- |
Acer Therapeutics Inc | 22.0M | -0.5x | --- |
BioRestorative Therapies Inc | 21.2M | -1.0x | --- |
Microbot Medical Inc | 20.6M | -1.2x | --- |
Company Information
Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.
Contact Information
- Headquarters
- 2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE, CA, United States 94005
- Phone
- 415-798-8589
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mike Raab
- President, Director
- Thomas Dubensky
- Chief Executive Officer, Director
- Stephen Brady
- Executive Vice President, Chief Medical Officer
- Samuel Whiting
- Vice President - Strategy and Finance
- Nicholas Maestas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 11.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $-2.67 |
Book Value | $1.72 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
